Your browser doesn't support javascript.
loading
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma.
Carpagnano, Giovanna Elisiana; Resta, Emanuela; Povero, Massimiliano; Pelaia, Corrado; D'Amato, Mariella; Crimi, Nunzio; Scichilone, Nicola; Scioscia, Giulia; Resta, Onofrio; Calabrese, Cecilia; Pelaia, Girolamo; Barbaro, Maria Pia Foschino.
Afiliación
  • Carpagnano GE; Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University "Aldo Moro" of Bari, Bari, Italy.
  • Resta E; Department of Economy, Translational Medicine and Health System Management, University of Foggia, Foggia, Italy.
  • Povero M; AdRes - Health Economics and Outcomes Research, Turin, Italy.
  • Pelaia C; Department of Health Sciences, Section of Respiratory Disease, University ''Magna Græcia'' of Catanzaro, Catanzaro, Italy.
  • D'Amato M; Department of Clinical Medicine and Surgery, University "Federico II" of Naples, Section of Respiratory Disease, "Monaldi Hospital", Naples, Italy.
  • Crimi N; Department of Internal Medicine and Specialist Medicine, Section of Respiratory Diseases, University of Catania, Catania, Italy.
  • Scichilone N; Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
  • Scioscia G; Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy. giulia.scioscia@unifg.it.
  • Resta O; Department of Basic Medical Sciences, Neuroscience and Sense Organs, Section of Respiratory Disease, University "Aldo Moro" of Bari, Bari, Italy.
  • Calabrese C; Department of Translational Medical Sciences, Section of Respiratory Disease, University of Campania "Luigi Vanvitelli", Naples, Italy.
  • Pelaia G; Department of Health Sciences, Section of Respiratory Disease, University ''Magna Græcia'' of Catanzaro, Catanzaro, Italy.
  • Barbaro MPF; Department of Medical and Surgical Sciences, Institute of Respiratory Diseases, University of Foggia, Foggia, Italy.
Sci Rep ; 11(1): 5453, 2021 03 09.
Article en En | MEDLINE | ID: mdl-33750842
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos / Anticuerpos Monoclonales Humanizados / Omalizumab Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Eosinofilia Pulmonar / Asma / Antiasmáticos / Anticuerpos Monoclonales Humanizados / Omalizumab Tipo de estudio: Health_economic_evaluation / Observational_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article País de afiliación: Italia